Maximum-strength ED treatment is usually considered when standard oral therapy feels inconsistent, underpowered, or too narrow in timing for the way a patient actually experiences erectile dysfunction. That clinical scenario is common enough to matter. Erectile function depends on adequate arterial inflow, nitric oxide signaling, cavernosal smooth-muscle relaxation, intact neural input, and appropriate sexual stimulation. When several of those variables are only partially supportive, some men do not need a completely different category of treatment so much as a different pharmacologic profile, one with a stronger on-demand effect and a longer usable window. That is where dual-PDE5 thinking becomes clinically interesting, provided it remains physician-supervised and safety-screened.
Maximum-Strength ED Treatment and the Problem of Incomplete Response
Most men with erectile dysfunction begin with a conventional PDE5 inhibitor strategy, because that remains the evidence-based first-line approach. Current expert guidance from the Fifth International Consultation on Sexual Medicine emphasizes that oral PDE5 inhibitors still anchor medical management for most men, but also notes that treatment should be individualized around efficacy, psychosocial context, safety, and patient preference [1]. That matters because “response” is not binary in real practice. A man may achieve some tumescence but lose rigidity too soon, may respond on one occasion and not the next, or may find that timing around meals, stress, and arousal is too unforgiving.
A 2024 review in the Cleveland Clinic Journal of Medicine summarized the problem clearly: up to 40% of men do not have a satisfactory response to PDE5 inhibitors, even though the class remains highly effective overall [2]. The reasons are varied. Some men take the medication incorrectly. Others are dealing with diabetes, hypertension, obesity, endothelial dysfunction, pelvic surgery history, low testosterone, or marked performance variability. In that context, a higher-intensity on-demand formula is not best understood as “more medication for everyone.” It is better understood as a more aggressive pharmacologic option for selected men whose erectile profile has not been adequately addressed by simpler approaches.
How Sildenafil and Tadalafil Differ Pharmacologically
Sildenafil and tadalafil belong to the same drug class, but they do not behave identically in the body. Both inhibit phosphodiesterase type 5, the enzyme that breaks down cyclic guanosine monophosphate (cGMP). By slowing cGMP degradation, they help preserve the nitric oxide signal that relaxes cavernosal smooth muscle and allows penile blood flow to increase during sexual stimulation. That common mechanism is the basis of their clinical use, but their kinetic patterns differ enough to shape patient experience.
Sildenafil is generally thought of as the more classic event-based agent. Landmark randomized trials established its efficacy across men with organic, psychogenic, and mixed erectile dysfunction, with clear benefits over placebo in erection quality and intercourse success [4]. Clinically, it is often favored when a patient wants a pronounced on-demand effect in a defined time window. Food can matter, particularly high-fat meals, which may delay onset and blunt the perceived peak.
Tadalafil is different mainly because it lasts longer. Comparative data and guideline reviews consistently describe tadalafil as the PDE5 inhibitor with the broadest therapeutic window, making it less tied to a narrow clock-based moment [1,5]. Men often prefer it for that reason. The effect profile can feel less compressed, which may reduce pressure around exact timing. A 2017 systematic review comparing tadalafil and sildenafil found broadly similar efficacy overall, but higher patient preference and improved sexual confidence with tadalafil in several analyses, likely because of that wider duration-of-action profile [5].
When those two pharmacologies are considered together, the rationale for a combined high-intensity formula becomes easier to understand. One ingredient is associated with a stronger on-demand peak profile, the other with longer persistence. The clinical appeal is not that they override physiology, because they do not. The appeal is that they may shape the timing and durability of a PDE5-mediated response differently than either agent alone.
Why a Dual-PDE5 Formula May Feel Different
In erectile medicine, drug response is often experienced in terms patients describe more simply as strength, speed, and staying power. Those are not technical terms, but they map onto real pharmacologic questions: how rapidly a medication reaches effective concentrations, how much PDE5 inhibition is present during the most relevant period of stimulation, and how long that support remains available.
A formula built around sildenafil 70 mg plus tadalafil 20 mg is therefore designed for an on-demand profile that is intentionally more forceful than entry-level therapy. The sildenafil component pushes toward a higher peak effect around the time of anticipated intercourse. The tadalafil component extends the window in which the nitric oxide-cGMP pathway remains pharmacologically supported. For men with mild, occasional, or clearly situational erectile dysfunction, that may be more intensity than they need. But for men with more severe rigidity loss, high response variability, or a repeated pattern of “partial success,” a stronger dual-mechanism profile can be clinically rational.
This concept also fits broader evidence on escalation strategies in difficult-to-treat erectile dysfunction. A 2021 systematic review and meta-analysis in JAMA Network Open reviewed 44 studies involving 3,853 men and found that combination strategies outperformed monotherapy on erectile-function scores without a significant overall increase in adverse events [6]. That review did not suggest that every man should stack oral agents indiscriminately. It did, however, reinforce an important principle: when ED is multifactorial or monotherapy-resistant, more tailored and mechanism-aware treatment plans can improve outcomes.
Who a Higher-Intensity On-Demand Formula May Suit
The men most likely to discuss a maximum-strength approach are usually not starting from zero. Many have already tried standard on-demand dosing, have learned something about their response pattern, and can describe the failure mode with some precision. Sometimes the erection begins but is not durable enough for intercourse. Sometimes the medication works only under nearly ideal circumstances. Sometimes the response is acceptable but too vulnerable to food, fatigue, alcohol, or anxiety. Those patterns suggest not just erectile dysfunction, but erectile dysfunction with a narrower margin for physiologic disruption.
Clinically, a higher-intensity on-demand formula may be considered in men with more severe vascular ED, metabolic comorbidity, inconsistent response to standard PDE5 dosing, or a preference for a stronger event-based strategy rather than a daily maintenance model. It may also appeal to men who want both a defined peak effect and less concern that a slightly delayed encounter will mean the opportunity is lost.
That does not mean it is appropriate for everyone. Men with unstable cardiovascular disease, men using nitrate therapy, and men with certain blood-pressure or medication-interaction risks may not be candidates at all. The 2024 Cleveland Clinic Journal of Medicine review is especially helpful here, because it reminds clinicians that dissatisfaction with oral therapy should trigger a more careful assessment, not reflexive dose escalation in isolation [2]. A higher-intensity formula makes sense only after screening the patient, verifying correct use, and deciding that the expected benefit outweighs the increased exposure.
How to Take It, and What Commonly Undermines the Response
Correct administration matters more than many men realize. PDE5 inhibitors do not generate erections in the absence of arousal, and they do not reliably rescue a setting dominated by heavy alcohol intake, severe fatigue, marked anxiety, or poor timing. The same 2024 Cleveland Clinic review notes that sildenafil should generally be taken 30 to 60 minutes before intercourse and works best on an empty stomach, while on-demand tadalafil is usually taken 30 to 120 minutes beforehand and is less affected by food [2]. Those practical details matter because a medication can appear ineffective when the real problem is delayed absorption, insufficient stimulation, or unrealistic timing expectations.
With a higher-intensity dual-PDE5 formula, those administration details become even more important. If sildenafil absorption is slowed by a large meal, the apparent advantage of the higher dose may be muted. If alcohol is substantial enough to blunt arousal and vasomotor coordination, a stronger formula may still disappoint. If the patient expects the medication to create desire or override stress physiology, the clinical experience will feel inconsistent even when the pharmacology is sound.
For that reason, the best use cases are typically men who already understand their response pattern and want a physician-guided formula designed around that pattern. In practice, that means setting expectations clearly: sexual stimulation is still required, planning still matters, and the medication profile works best when major antagonists such as heavy alcohol, high-fat meals, or severe sleep deprivation are not competing against it.
Safety, Contraindications, and the Broader Vascular Context
The safety discussion is at least as important as the efficacy discussion. Sildenafil and tadalafil can both produce dose-related adverse effects including headache, flushing, dyspepsia, nasal congestion, and dizziness. Blood-pressure lowering is usually modest in appropriate patients, but it can become clinically significant when PDE5 inhibitors are combined with nitrates or used in men whose cardiovascular status makes vasodilation unsafe. That is why physician review is not merely a legal step, it is the mechanism that separates structured prescribing from unsafe self-experimentation.
There is also a broader vascular point worth noting. Erectile dysfunction often travels with endothelial dysfunction, insulin resistance, hypertension, and other cardiometabolic stressors. A 2024 observational study in The American Journal of Medicine reported that tadalafil and sildenafil use in men with erectile dysfunction was associated with lower risks of all-cause mortality, myocardial infarction, stroke, venous thromboembolism, and dementia, with particularly strong signals for tadalafil in some analyses [3]. These data do not prove that PDE5 inhibitors should be used as preventive cardiovascular therapy. They do, however, support a bigger clinical truth: ED medications act on a pathway that is vascular, not merely sexual.
That perspective helps explain why some men need more than a simple prescription. If a patient has persistent ED alongside obesity, hypertension, poor sleep, excess alcohol use, or probable testosterone deficiency, a stronger formula may improve symptom control, but it should still sit inside a larger medical plan. Better blood pressure control, improved sleep, weight reduction, lower alcohol intake, and a hormonal workup when indicated remain central to durable results.
Conclusion
A maximum-strength on-demand formula that combines sildenafil 70 mg with tadalafil 20 mg is best understood as a deliberately engineered PDE5 profile rather than a generic escalation. The sildenafil component is intended to intensify the peak on-demand response. The tadalafil component is intended to widen the functional window. For carefully selected men, especially those with incomplete response to simpler regimens, that combination can be clinically rational. But its value depends on appropriate patient selection, correct administration, realistic expectations, and physician oversight of contraindications and interaction risk.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans starting with a free online assessment at questionnaire.getonyxmd.com. You can also review Mach 1 or browse the blog.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
- Stern N, Bajic P, Campbell J, et al. Evolving medical management of erectile dysfunction: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024). Sexual Medicine Reviews. 2025;13(4):513-537. doi:10.1093/sxmrev/qeaf035
- Bajic P, Capogrosso P. What are options for my patients with erectile dysfunction who have an unsatisfactory response to PDE5 inhibitors? Cleveland Clinic Journal of Medicine. 2024;91(11):667-670. doi:10.3949/ccjm.91a.24005
- Jehle DVK, Sunesra R, Uddin H, et al. Benefits of Tadalafil and Sildenafil on Mortality, Cardiovascular Disease, and Dementia. The American Journal of Medicine. 2024. doi:10.1016/j.amjmed.2024.10.039
- Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. New England Journal of Medicine. 1998;338(20):1397-1404. doi:10.1056/NEJM199805143382001
- Gong B, Ma M, Xie W, et al. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. International Urology and Nephrology. 2017;49(10):1731-1740. doi:10.1007/s11255-017-1644-5
- Mykoniatis I, Pyrgidis N, Sokolakis I, et al. Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-analysis. JAMA Network Open. 2021;4(2):e2036337. doi:10.1001/jamanetworkopen.2020.36337
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.